AstraZeneca (AZN) Receives “Hold” Rating from Shore Capital
Several other analysts have also recently weighed in on AZN. JPMorgan Chase & Co. set a GBX 5,800 ($75.55) price target on shares of AstraZeneca and gave the company a buy rating in a research note on Monday, May 28th. Liberum Capital reissued a hold rating on shares of AstraZeneca in a research note on Wednesday, May 30th. Goldman Sachs Group set a GBX 3,750 ($48.85) price target on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, May 30th. Deutsche Bank reissued a buy rating on shares of AstraZeneca in a research note on Wednesday, June 6th. Finally, Citigroup reissued a buy rating on shares of AstraZeneca in a research note on Friday, June 8th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 5,689.45 ($74.11).
AstraZeneca stock opened at GBX 5,669 ($73.84) on Monday. AstraZeneca has a 1-year low of GBX 4,260 ($55.49) and a 1-year high of GBX 5,520 ($71.90).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: NASDAQ
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.